Patient Guide: A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 47 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06863272
Status: 🟢 Enrolling Now
Condition: Castration-Resistant Prostatic Cancer, Metastasis
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 47 locations across the country.

Top locations include:
  • • Washington D.C., District of Columbia
  • • Germantown, Tennessee
  • • Ciudad Autónoma de Buenos Aires, Buenos Aires
  • • And 44 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) - Join Clinical Trial NCTNCT06863272

How to Join This Clinical Trial - NCTNCT06863272

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Castration-Resistant Prostatic Cancer, Metastasis. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Castration-Resistant Prostatic Cancer, Metastasis. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Castration-Resistant Prostatic Cancer, Metastasis
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06863272 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 47 locations. Find a study site near you:

Clinical Research Site

Washington D.C., District of Columbia 20010 - United States

Status: RECRUITING

Clinical Research Site

Germantown, Tennessee 38138 - United States

Status: RECRUITING

Clinical Research Site

Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ - Argentina

Status: RECRUITING

Clinical Research Site

La Rioja, F5300COE - Argentina

Status: RECRUITING

Clinical Research Site

Macquarie University, New South Wales 2109 - Australia

Status: RECRUITING

Clinical Research Site

Natal, Rio Grande do Norte 59062-000 - Brazil

Status: RECRUITING

Clinical Research Site

Porto Alegre, Rio Grande do Sul 90020-090 - Brazil

Status: RECRUITING

Clinical Research Site

Porto Alegre, Rio Grande do Sul 90035-001 - Brazil

Status: RECRUITING

Clinical Research Site

Bragança Paulista, São Paulo 12916-542 - Brazil

Status: RECRUITING

Clinical Research Site

São José do Rio Preto, São Paulo 15090-000 - Brazil

Status: RECRUITING

And 37 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Castration-Resistant Prostatic Cancer, Metastasis:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships